Table 5.

Correlation between mean percentage dose and top 5 symptom mean scores at specific time points

	Dasatinib						Nilotinib						Ponatinib
	6		12		18		6		12		18		6		12		18
	obs = 48 [dose = 94%]		obs = 56 [dose = 88%]		obs = 74 [dose = 85%]		obs = 12 [dose = 88%]		obs = 21 [dose = 83%]		obs = 46 [dose = 81%]		obs = 50 [dose = 74%]		obs = 19 [dose = 53%]		obs = 21 [dose = 20%]
	r	P	r	P	r	P	r	P	r	P	r	P	r	P	r	P	r	P
Fatigue	−0.07	0.63	0.35	0.009	0.36	0.002	−0.70	0.011	−0.006	0.98	−0.1	0.49	0.15	0.29	0.21	0.35	0.6	0.006
Drowsiness	0.05	0.72	0.28	0.04	0.32	0.005	−0.95	<.0001	−0.21	0.35	−0.23	0.11	0.24	0.09	0.29	0.22	0.62	<.0001
Sleep disturbance	−0.03	0.84	0.25	0.068	0.28	0.015	−0.34	0.29	−0.09	0.68	−0.24	0.1	0.15	0.28	−0.003	0.99	0.38	0.19
Pain	−0.06	0.67	0.17	0.19	0.20	0.08	0.09	0.77	−0.26	0.24	−0.19	0.18	−0.002	0.99	0.13	0.54	0.37	0.12
Difficulty remembering	0.07	0.63	0.19	0.15	0.29	0.01	−0.78	0.002	−0.36	0.1	−0.4	0.007	0.35	0.01	0.1	0.66	0.5	0.36

Obs, observations.

Six, 12, and 18 mo were the most relevant time points with large effect size and significant correlation. The resting time points (3, 9, and 24 mo) did not show any significant correlation between mean dose percentage and symptom scores.